----item----
version: 1
id: {AEEB7C6B-A968-4825-961F-5C6E192F548B}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/VC Funding 2014
parent: {D5B965D3-AC3D-4A7F-90E6-65193022C6B5}
name: VC Funding 2014
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: fdf7266b-bc4e-462e-8c0e-a67081dd51ac

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 968

<p>  <tbody> <tr> </tr> <tr> <td> <tbody> <tr> <td>Are you betting on medtech's hottest areas?<a></a><br> <em>By Tina Tan, Editor</em><br> Find out who's investing in what with Clinica's venture/growth financing table, updated regularly with the latest investment deals. </td> </tr> <tr> <td><b>VC Funding 2014</b></td> <td><a><b>VC Funding 2013</b></a></td> <td><b><a>VC Funding 2012</a></b></td> <td><b><a>FREE TRIAL</a></b></td> </tr> </tbody> </td> </tr> <tr> <td><a></a></td> <td><div><a></a></div></td> <td><a></a></td> <td><div><a></a></div></td> <td><a></a></td> <td><a></a></td> <td><a></a></td> <td><a></a></td> </tr> <tr> <td><div><a>Deals</a></div></td> <td><div><a>MandA </a></div></td> <td><div><a>Financials</a></div></td> <td><div><a>Funding </a></div></td> <td><div><a>Legal</a></div></td> <td><div><a>Start-ups and SMEs </a></div></td> <td><div><a>Market Monitor </a></div></td> <td><div><a>Google Map: MandA 2010 </a></div></td> </tr> </tbody>  </p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 15

VC Funding 2014
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 123406

<p> <table> <tbody> <tr> </tr> <tr> <td colspan="8" scope="row" widtd="101"><table> <tbody> <tr> <td colspan="4" scope="row" widtd="101">Are you betting on medtech's hottest areas?<a name="top" id="top"></a><br> <em>By Tina Tan, Editor</em><br> Find out who's investing in what with Clinica's venture/growth financing table, updated regularly with the latest investment deals. </td> </tr> <tr> <td bgcolor="#cccccc" scope="row" widtd="101"><b>VC Funding 2014</b></td> <td bgcolor="#666666" scope="row" widtd="101"><a href="http://www.clinica.co.uk/VC-Funding/VC_2013/" class="optionsLink"><b>VC Funding 2013</b></a></td> <td bgcolor="#666666" scope="row" widtd="101"><b><a href="http://www.clinica.co.uk/VC-Funding/_2012/" class="optionsLink">VC Funding 2012</a></b></td> <td bgcolor="#666666" scope="row" widtd="101"><b><a href="http://www.clinica.co.uk/freetrial/" class="optionsLink">FREE TRIAL</a></b></td> </tr> </tbody> </table></td> </tr> <tr> <td><a href="http://www.clinica.co.uk/business/"><img src="-/media/A41DB0E6789340E3BBE2BB586EBE4293.ashx" alt="Deals" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/manda/"><img src="-/media/1594690D6C314ABFA668C2F281D90DEC.ashx" alt="MandA" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></div></td> <td><a href="http://www.clinica.co.uk/business/financials/"><img src="-/media/873669F6772642DC9C0C091A39B44486.ashx" alt="Financials" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><div><a href="http://www.clinica.co.uk/business/funding/"><img src="-/media/B1AB1227A20C433897DB3C8B2F140E45.ashx" alt="Funding" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></div></td> <td><a href="http://www.clinica.co.uk/business/legal/"><img src="-/media/7D0516FC157A4E1F896F543962188904.ashx" alt="Legal" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/business/start-upssmes/"><img src="-/media/66EE0878ED2E4CEC9D21449351C40077.ashx" alt="Start-ups and SMEs" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/business/marketmonitor/"><img src="-/media/808B4B2204F542438455FA3DB83F4C28.ashx" alt="Market Monitor" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> <td><a href="http://www.clinica.co.uk/ma2/"><img src="-/media/7183F022AB364B8C8C43E7EC13518288.ashx" alt="Google Map" width="80" height="80" border="0" style="margin-left: 5px; margin-right: 5px; margin-bottom: 5px"></a></td> </tr> <tr> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/" class="optionsLink">Deals</a></div></td> <td scope="row" widtd="101"><div><a href="http://www.clinica.co.uk/business/manda/" class="optionsLink">MandA </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/financials/" class="optionsLink">Financials</a></div></td> <td><div><a href="http://www.clinica.co.uk/business/funding/" class="optionsLink">Funding </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/legal/" class="optionsLink">Legal</a></div></td> <td><div><a href="http://www.clinica.co.uk/business/start-upssmes/" class="optionsLink">Start-ups and SMEs </a></div></td> <td><div><a href="http://www.clinica.co.uk/business/marketmonitor/" class="optionsLink">Market Monitor </a></div></td> <td><div><a href="http://www.clinica.co.uk/ma2/" class="optionsLink">Google Map: MandA 2010 </a></div></td> </tr> </tbody> </table> </p> <p> &nbsp; </p> <table> <tr bgcolor="#C5E2E2"> <th scope="col"> <p> <b>Company</b> </p> </th> <th scope="col"> <p> <b>State</b> </p> </th> <th scope="col"> <p> <b>Country</b> </p> </th> <th scope="col"> <p> <b>Sector</b> </p> </th> <th scope="col"> <p> <b>Technology</b> </p> </th> <th scope="col"> <p> <b>Investors<br> to date</b> </p> </th> <th scope="col"> <p> <b>Amount<br> raised</b> </p> </th> <th scope="col"> <p> <b>Financing<br> round</b> </p> </th> <th scope="col"> <p> <b>Total investment</b> </p> </th> </tr> <tr> <td> <p> <b>JANUARY</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Shockwave Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiovascular </p> </td> <td> <p> The Lithoplasty balloon catheter system to treat highly calcified vascular and valvular disease. </p> </td> <td> <p> Sofinnova Partners </p> </td> <td> <p> $12.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> AqueSys </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The XEN Gel stent is designed to treat glaucoma. </p> </td> <td> <p> Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures, SV Life Sciences and other investors </p> </td> <td> <p> $43.6m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Michelson Diagnostics </p> </td> <td> <p> Kent </p> </td> <td> <p> UK </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> The ViVoSight device uses optical coherence tomography to diagnose and monitor skin cancer. The device is CE-marked and FDA-cleared. </p> </td> <td> <p> Octopus Investments, Catapult Venture Managers, London Business Angels and other investors </p> </td> <td> <p> GBP1.98m ($3.25m) </p> </td> <td> <p> Series A2 </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Cohera Medical </p> </td> <td> <p> PA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> The TissueGlu surgical adhesive, CE- marked and currently sold in Germany, targets the large flap procedures such as abdominoplasty. The Sylys surgical sealant, not yet CE-marked, is for reducing anastomotic leakage in gastrointestinal procedures. </p> </td> <td><p></td> <td> <p> $9.3m </p> </td> <td> <p> Part of a $26.3m series D </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ZipLine Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> The Zipline surgical skin closure device is a suturing product designed to significant cut treatment time. There are also no sutures to remove, post-surger, with the Zipline. </p> </td> <td> <p> RA Capital Management, XSeed Capital, Calremont Creek Venture and others </p> </td> <td> <p> $4.3m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Metabolon </p> </td> <td> <p> NC </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Metabolon offers a range of metabolomics-based diagnostic tests, including Prostarix, a urine-based taest to assess a patient's likelihood of having prostate cancer if they already have slightly elevated PSA levels. </p> </td> <td> <p> Camden PArtners, Sumitomo, Aurora Funds, Harris &amp; Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners </p> </td> <td> <p> $15m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> FIRE1 </p> </td> <td> <p> Dublin </p> </td> <td> <p> Ireland </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> FIRE1 is a spin-out of medical device incubator, The Foundry. No details have been publicly disclosed about its technology but it may be cardiovascular, seeing Covidien's Vascular Therapies president being on the board. </p> </td> <td> <p> Covidien, Lightstone Ventures, New Enterprise Associates </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Omicia </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Opal is a healthcare IT platform designed for analytical genome interpretation. </p> </td> <td> <p> Artis Ventures, Acadia Woods PArtners, Bay City Capital, Buchanan Investments, Casdin Capital </p> </td> <td> <p> $6.8m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Avelas Biosciences </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> The first product from the Avelas Cancer Illuminator platform, AVB-620, is a fluorescent peptide that delivers real-time intraoperative cancer diagnosis in the form of a luminous map, enabling surgeons to make a decision during first surgery. </p> </td> <td> <p> Avalon Ventures, Torrey Pines, WuXi AppTec and other investors </p> </td> <td> <p> $6.85m </p> </td> <td> <p> Series B </p> </td> <td> <p> $14m </p> </td> </tr> <tr> <td> <p> SuperSonic Imagine </p> </td> <td> <p> Aix-en-Provence </p> </td> <td> <p> France </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> The CE-marked and US FDA-cleared Aixplorer ultrasound system uses ShearWave elastography to image and measure tissue stiffness, and in turn diagnose various cancers including breast, thyroid, abdomen, liver, among others. </p> </td> <td> <p> Norgrine Ventures, EdRIP, Auriga Partners, Omens Capital, NBGI Ventures, Bioam, Merieux Developpement, Wellington Partners, Innobio, IXO Private Equity and BPIFrance. </p> </td> <td> <p> Euros5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Onciomed </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Obesity management </p> </td> <td> <p> The Gastic Vest System, designed as a reversible, safer alternative to bariatric surgery, is placed around the stomach to restrict the amount of food intake. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Ivantis </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The Hydrus microstent is designed to lower intraocular pressure for glaucoma patients. </p> </td> <td> <p> Vertex Ventures, GBS Ventures, Ascension Ventures, Vertex Ventures, GBS Ventures, EDBI, MemorialCare Innogation Fund, New Enterprise Associates, Delphi Ventures </p> </td> <td> <p> $14m </p> </td> <td> <p> Part of a $46.5m series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> eNeura Therapeutics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Neurostimulation </p> </td> <td> <p> The Cerena transcranial magnetic stimulator is cleared by the US FDA for noninvasive treament of migraine. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> DNAnexus </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Genomic analytics </p> </td> <td> <p> DNAmexu offers a cloud platform for labs to manage data, including genotypic and phenotypic data; to facilitiate collaboration between researers and access diverse reference datasets. </p> </td> <td> <p> Claremont Creek Ventures, Google Ventures, TPG Biotech, First Round Capital </p> </td> <td> <p> $15m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> OneBreath </p> </td> <td> <p> Bangalore </p> </td> <td> <p> India </p> </td> <td> <p> Critical care </p> </td> <td> <p> OneBreath's portable and rechargeable ventilators are only a fifth of the cost of regular ventilators. </p> </td> <td> <p> Ventureast Tenet Fund and angel investors </p> </td> <td> <p> INR18 crore ($2.9m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Stratos Genomics </p> </td> <td> <p> WA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Stratos' Sequencing By Xpansion sequencing metthod which converts DNA into a surrogate molecule called Xpandomer that is read via a nanopore detector. </p> </td> <td> <p> Fisk Ventures and others </p> </td> <td> <p> $2m </p> </td> <td> <p> Series A5 </p> </td> <td> <p> Around $10m </p> </td> </tr> <tr> <td> <p> Biodesix </p> </td> <td> <p> CO </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The VeriStrat serum protein test helps guide therapy for advanced non small cell lung cancer. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6.1m </p> </td> <td> <p> Part of a $14.4m series E </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ArthroMeda </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Formerly known as ArthroCAD, ArthroMeda develops devices for total hip arthroplasties. </p> </td> <td> <p> GTCR and others </p> </td> <td> <p> $1.6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> LensAR </p> </td> <td> <p> FL </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The LensAR laser system is the only femtosecond cataract laser built specifically for refractive cataract surgery. </p> </td> <td> <p> Aisling Capital, Florida Growth, Florida Opportunity Funds, TopCon, and others </p> <p></td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Cambridge Endoscopic Devices </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> Cambridge Endo offers a range of devices for single-incision laparoscopy procedures. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.9m (including debt) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Forus Health </p> </td> <td> <p> Bangalore </p> </td> <td> <p> India </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The 3nethra device is a low-cost, quick eye scanner for diagnosting ophthalmic conditions including refractive errors, glaucoma, cataracts, corneal problems and diabetic retinopathy </p> </td> <td> <p> Asian Healthcare Fund, Accel Partners, IDG Ventures India </p> </td> <td> <p> $8m </p> </td> <td> <p> Series B </p> </td> <td> <p> $13m </p> </td> </tr> <tr> <td> <p> Maverix Biomics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Genomic analytics </p> </td> <td> <p> The Maverix Analytic Platform is designed to integrate management, exploration, and visualization of genomic data in one easy-to-use system. </p> </td> <td> <p> Asset Management Ventures and private investors </p> </td> <td> <p> $6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ActX </p> </td> <td> <p> WA </p> </td> <td> <p> US </p> </td> <td> <p> Genomic analytics </p> </td> <td> <p> ActX says it is focused on &quot;making actionable patient genomic information truly useful in everyday medical practice.&quot; </p> </td> <td> <p> Seattle Angel Group and other investors </p> </td> <td> <p> $1.9m </p> </td> <td> <p> Seed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> PowerVision </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The FluidVision accommodative intraocular lens, is in clinical trials. The implant claims to restore true accommodation and allows wearers to focus vision on near objects. </p> </td> <td> <p> Medtronic, Johnson &amp; Johnson and others </p> </td> <td> <p> $20m </p> </td> <td> <p> Series D1 </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>FEBRUARY</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Guardant Health </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The Guardant360 test enables more targeted cancer treatment by tracking disease progression in real time. </p> </td> <td> <p> Sequoia Capital </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Edinburgh Molecular Imaging </p> </td> <td> <p> Edinburgh </p> </td> <td> <p> UK </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> EMI id developing fluorescent imaging agents to help diagnose and track respiratory conditions, from lung cancer to lung infections and fibrosis. </p> </td> <td> <p> Epidarex Capital </p> </td> <td> <p> &pound;4m ($6.6m) </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> HTG Molecular Diagnostics </p> </td> <td> <p> AZ </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The HTG Edge system is an automated RNA analysis platform. </p> </td> <td> <p> Novo Ventures, SROne, Merck Capital Ventures, Fletcher Spaght </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Miramar Labs </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Dermatology </p> </td> <td> <p> The miraDry system is designed to treat overactive underarm sweat glands. It is a noninvasive alternative to surgery and injection therapies. </p> </td> <td> <p> Aisling Capital, Cross Creek Capital, Domain Associates, Morgenthaler Ventures, RusnanoMedInvest </p> </td> <td> <p> $10m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Perceptis Medical </p> </td> <td> <p> MN </p> </td> <td> <p> US </p> </td> <td> <p> ENT </p> </td> <td> <p> The Perceptis ear tube introduce is a surgical tool used in pediatric tympanostomy surgery. The device is designed to eliminate the need for general anaethesia during the procedure. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Pulse Therapeutics </p> </td> <td> <p> MO </p> </td> <td> <p> US </p> </td> <td> <p> Neurology </p> </td> <td> <p> Pulse is developing a magnet based technology for dissolvig blood clots in stroke patient and improve the delivery of thrombolytic. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Tenaxis Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery/Wound closure </p> </td> <td> <p> The ArterX sealant for vascular procedures uses a prophylactic agent that bind to proteins in bothe the sealant and the tissue to cross link them. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Intuity Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> The POGO blood glucose monitoring system integrates test strips and lancing device into one system. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Advanced Accelerator Applications </p> </td> <td> <p> Saint-Genis-Pouilly </p> </td> <td> <p> France </p> </td> <td> <p> Molecular medicine </p> </td> <td> <p> AAA's portfolio includes diagnostic and therapeutic products, with a focus on molecular imaging and personalized medicines for the treatment of diseases such as cancer. </p> </td> <td> <p> HBM Healthcare Investments, Tamburi Investment Partners and other private and institutional investors </p> </td> <td> <p> &euro;41 </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> GC Aesthetics </p> </td> <td> <p> Dublin </p> </td> <td> <p> Ireland </p> </td> <td> <p> Medical aesthetics </p> </td> <td> <p> GC is the umbrella company for two breast implant manufacturers, Nagor and Eurosilicone </p> </td> <td> <p> OrbiMed, Montreux Equity Partners, Oyster Capital </p> </td> <td> <p> $60m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Kerecis </p> </td> <td> <p> Reykjavik </p> </td> <td> <p> Iceland </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> Kerecis is developing the MariGen Omega3, an intact decellularized fish skin that is used as for making tissue repair products. </p> </td> <td> <p> NSA Ventures, Omega3, Novator, Capital, 1924, Skogur, Kolfningur, Hradfrystihusid-Gunnvor </p> </td> <td> <p> $2m </p> </td> <td> <p> Series A3 </p> </td> <td> <p> Undislcosed </p> </td> </tr> <tr> <td> <p> NxThera </p> </td> <td> <p> MN </p> </td> <td> <p> US </p> </td> <td> <p> Men's health </p> </td> <td> <p> The Rez?m system employs NxThera's Convective WAVE (water vapor energy) technology to treat benign prostatic hyperplasia. The underlying technology can also be applied for treatment of prostate and kidney cancers. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> over $2m </p> </td> <td> <p> Series C2 </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Cheetah Medical </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> The Cheetah Nicom hemodynamic management system is based on proprietary bioreactance technology and offers a completely noninvasive method of monitoring key hemodynamic paraments. </p> </td> <td> <p> Fletcher Spaght Ventures, Springfield Investment Management, MVM Life Science Partners, Robert Bosch Venture Capital and Ascension Health Ventures </p> </td> <td> <p> $9m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Quanttas </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Quanttas' wearable technologies for vital signs monitoring </p> </td> <td> <p> Khosla Ventures, Matrix Partners </p> </td> <td> <p> $19m </p> </td> <td> <p> Series A </p> </td> <td> <p> $24m </p> </td> </tr> <tr> <td> <p> Evena Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Imaging </p> </td> <td> <p> Evena's range of vascular imaging technologies are designed to facilitate fast, accurate and precise intravenous access. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $15m </p> </td> <td> <p> Part of a $15m series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Pursuit Vascular </p> </td> <td> <p> MN </p> </td> <td> <p> US </p> </td> <td> <p> Anti-infection technologies for catheters </p> </td> <td> <p> ClearGuard HD is an antimicrobila rod that is inserted into hemodialysis catheters to kill infections </p> </td> <td> <p> Undislcosed </p> </td> <td> <p> $1.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Seno Medical Instruments </p> </td> <td> <p> TX </p> </td> <td> <p> US </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> The Imagio breast imaging device uses opto-acoustic imaging technology plus conventional ultrasound to obtain a blood map in anad around suspicious breast masses and help in diagnosis of breast cancer. </p> </td> <td> <p> Medcare Invesment Funds and others </p> </td> <td> <p> $34.6m </p> </td> <td> <p> Part of a $36m series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Bruin Biometrics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Diagnostics/patient monitoring </p> </td> <td> <p> Bruin's biometric scanning technology is employed in two devices: the SEM Scanner, a wound care diagnostic device to detec inflammatory changes assoicated with pressure induced tissue damage and OrthoSonos, a device to diagnostic and spot monitor the health of joint and prosthetic implants. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>MARCH</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Augmedix </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> Augmedix is developing ways to use Google Glass in healthcare. The first application is to help improve doctors' workflow. </p> </td> <td> <p> DCM, Emergence Capital Partners </p> </td> <td> <p> $3.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Blue Earth Diagnostics </p> </td> <td> <p> London </p> </td> <td> <p> UK </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Blue Earth is developing PET tracer agents for imaging recurrent prostate cancer. </p> </td> <td> <p> Syncona Partners </p> </td> <td> <p> &pound;12.8m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> QuanDx </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The Q-Fusion leukenia fusion gene screening kit is QuanDx's first product from its Yin-Yang probe technology. Q-fusion can detect 32 fusion genes simultaneously. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.25m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Exosome Diagnostics </p> </td> <td> <p> NY </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Exosome is developing noninvasive fluid-based molecular diagnostics for various cancers and neurodegenerative diseases. Its first product is a urine-based test for prostate cancer and the other is a blood based test for non-small cell lung cancer. </p> </td> <td> <p> Qiagen, Arcus Ventures, Tiger PArtners, CD Ventures, Monashee Capital, b-to-v Partners, NGN Capital and Forbion Capital Partners </p> </td> <td> <p> $27m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> BiO2 MEdical </p> </td> <td> <p> TX </p> </td> <td> <p> US </p> </td> <td> <p> Cardio/peripheral vascular </p> </td> <td> <p> BiO2's Angel catheter is a combination of a central venous catheter and an inferior vena cava filter. The device is designed to trap and remove blood clots. </p> </td> <td> <p> Targeted Technology Fund, Texas Emerging Technology Fund and others </p> </td> <td> <p> $5.9m </p> </td> <td> <p> Series D </p> </td> <td> <p> $28m </p> </td> </tr> <tr> <td> <p> Svelte Medical Systems </p> </td> <td> <p> NJ </p> </td> <td> <p> US </p> </td> <td> <p> Cardio/peripheral vascular </p> </td> <td> <p> The Svelte integrated delivery system comprises a wire, balloon and stent and is claimed to have the lowest-crimped-stent profile. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $70m </p> </td> </tr> <tr> <td> <p> OnTarget Laboratories </p> </td> <td> <p> IN </p> </td> <td> <p> US </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> OnTarget has developed an optical imaging technology, that employs small-molecule ligands, to light up tumors and enable surgeons to remove more cancerous tissue. </p> </td> <td> <p> Pension Fund of the Christian Church, Old World Industries and others </p> </td> <td> <p> $15m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> RainDance Technologies </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> RainDance specialises in Digital PCR and next generation targeted sequencing. </p> </td> <td> <p> GE Ventures, Northgate Capital, Myriad Genetics, Mohr Davidow Ventures, Quaker BioVentures, Alloy Ventures, Acadia Woods Partners, Sectoral Asset Maangement, Capital Royalty Partners </p> </td> <td> <p> $16.5m </p> </td> <td> <p> Series E </p> </td> <td> <p> Over $100m </p> </td> </tr> <tr> <td> <p> EarLens </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> ENT </p> </td> <td> <p> EarLens is developing a hearing aid that uses infrared technology. </p> </td> <td> <p> Medtronic and others </p> </td> <td> <p> $36m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Domain Surgical </p> </td> <td> <p> UT </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> Domain's Ferromagnetic surical system uses the power of ferromagnetic heating to allow soft tissue cutting and coagulation. </p> </td> <td> <p> OrbiMed, BioStar Ventures, an unnamed strategic investors and others </p> </td> <td> <p> $46.6m (includes debt financing) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Recombine </p> </td> <td> <p> NY </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The CarrierMap microarray tests patients for mutations associated with 213 genetic diseases. The product is targeted at fertility clinics. </p> </td> <td> <p> FirstMark Capital, Vast Ventures and others </p> </td> <td> <p> $3.3m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Invuity </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> Invuity develops visualization tools for minimally invasive and minimal access surgeries. </p> </td> <td> <p> HealthCare Royalty Partners, Valence Life Sciences, InterWest PArtners, Kleiner Perkins Caufield and Byers </p> </td> <td> <p> $21m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> BioTrace Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> BioTrace is developing a temporary cardiac pacing device to treat reversible symptomatic bradycardia. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> NinePont Medical </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> the Nvision VLE imaging system allows physicians to endoscopically vies real-time, high resolution, cross-sectional images of organs and tissues up to 3mm deep. </p> </td> <td> <p> Corning, third Rock Ventures, Prospect Venture Partners </p> </td> <td> <p> $34m </p> </td> <td> <p> Series B </p> </td> <td> <p> $57m </p> </td> </tr> <tr> <td> <p> Oculeve </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Oculeve is developing an eye implant that stimulates the lacrimal glands to spur tear production. </p> </td> <td> <p> Kleiner Perkins Caufield &amp; Byers, Versant Ventures and New Enterprise Associates. </p> </td> <td> <p> $16.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $33.2m </p> </td> </tr> <tr> <td> <p> Tyto Care </p> </td> <td> <p> Netanya </p> </td> <td> <p> Israel </p> </td> <td> <p> Mobile health/ remote patient monitoring </p> </td> <td> <p> Tyto has developed remote monitoring system consisting of a handheld device that collects and transmits a broad range of physiological readings and a cloud-based communication platform </p> </td> <td> <p> Orbimed </p> </td> <td> <p> $4m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> CellPly </p> </td> <td> <p> Bologna </p> </td> <td> <p> Italy </p> </td> <td> <p> IVD </p> </td> <td> <p> CellPly's develops diagnostic tools that allow clinicians to assess in vitro a patient's cellular response to cancer treatment </p> </td> <td> <p> Itlaian Angels for Growth, Zernike Meta Ventures, Atlas Seed </p> </td> <td> <p> &euro;2m </p> </td> <td> <p> Seed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Axonics Modulation Technologies </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Neuromodulation </p> </td> <td> <p> Axonics has exclusive licence to a miniaturized implantable neuromodulation technology and will target various markets including the treatment of chronic pain and overactive bladder. </p> </td> <td> <p> Edmond de Rothschild Investment Partners, NeoMed Management, Legend Capital and private investors </p> </td> <td> <p> $32.6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Invendo Medical </p> </td> <td> <p> Kissing </p> </td> <td> <p> Germany </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> The Invendoscope is a singl-use colonoscopic that has a robotic &quot;gentle drive&quot; technology that exerts less pressure on the colon wall than conventional colonoscopes. </p> </td> <td> <p> Xeraya Capital, TVM Capital,Wellington Partner, 360? Capital and private investors </p> </td> <td> <p> &euro;20.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Vigilant Biosciences </p> </td> <td> <p> FL </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Vigilant has developed a rinse-and-spit test for assessing early risk of oral cancer. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Veran Medical </p> </td> <td> <p> MO </p> </td> <td> <p> US </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> The SPiNDrive system is an electromagnetic navigation platform that allows physician to biopsy solitary pulmonary nodules for potential early diagnosis of lung cancer. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.9m </p> </td> <td> <p> Undisclosed </p> </td> <td><p></td> </tr> <tr> <td> <p> NeuMoDx Molecular </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The NeuMoDx 500 Molecular IVD system is a fully automated, random-access platform designed to perform high throughput, low-cost molecular testing. It is currently in development stage. </p> </td> <td> <p> Pfizer Ventures, Baird Capital, Venture Investors, Arboretum Ventures, Wolverine Venture Fund </p> </td> <td> <p> $21m </p> </td> <td> <p> Series B </p> </td> <td> <p> $26m </p> </td> </tr> <tr> <td> <p> Auris Surgical Robotics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> Auris is developing a surgical robot for ophthalmological procedures. </p> </td> <td> <p> Mithril Capital MAnagement, Highland Cpaital PArtners, Lux Capital, Navimed Capital, among others </p> </td> <td> <p> $34.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>APRIL</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Providence Medical Technology </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Providence is commercializing its DTRAX platform of minimally invasive cervial implants and instruments are used to treat cervical degenerative disc disease through indirect decompression and fusion. </p> </td> <td> <p> Stanmore Medical Investments, Aphelion Capital, RCT Ventures </p> </td> <td> <p> $6.8m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Transcend Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The CyPass microstent is underoing US clinical trials. It is designed for management of glaucoma. </p> </td> <td> <p> Investor Growth Capital, HLM Venture Partners, Morgenthaler, Canaan Partners, Kaiser Permanente, Split Rock Partners, Finistere Ventures, Latterell Venture Partners, Technology Partners, and various pharma and medtech corporate investors </p> </td> <td> <p> $22m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Mirada Medical </p> </td> <td> <p> Oxford </p> </td> <td> <p> UK </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Mirada develops and sells imaging software worldwide. </p> </td> <td> <p> Albion Ventures </p> </td> <td> <p> $1.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> RefleXion Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Oncology </p> </td> <td> <p> RefleXion is developing a biologically-guided radiation therapy system for cancer treatment. It integrates PET with radiation therapy. </p> </td> <td> <p> Sofinnova Partners, Pfizer Venture Investments, Venrock </p> </td> <td> <p> $11.6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> DNA Electronics </p> </td> <td> <p> London </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> DNA is developing the Genalysis point- of-care genomic diagnostic product line, based on label-free semconductor sequencing technology. </p> </td> <td> <p> Genting Berhad </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> SI-BONE </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> The CE-marked and 510(k)-cleared iFuse implant system is a minimally invasive surgical device for fusing the sacroiliac (SI) joint. </p> </td> <td> <p> Orbimed, Novo, Skyline Ventures, Montreux Equity Partners </p> </td> <td> <p> $33m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Sequana Medical </p> </td> <td> <p> Zurich </p> </td> <td> <p> Switzerland </p> </td> <td> <p> Fluid management </p> </td> <td> <p> Sequana's CE-marked alfapump implantable, battery-powered pump system is designed to manage ascites, the build up of abdominal fluid due to liver cirrhosis and certain cancers. The pump automatically and continuously move the excess fluid from the abdominal cavity to the bladder where it is naturally passed out. </p> </td> <td> <p> Life Science Partners, NeoMed Management, VI Partners, BioMedInvest, Entrepreneurs Fund, Capricorn Venture Partners. </p> </td> <td> <p> CHF23m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Genomind </p> </td> <td> <p> PA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Genomind is developing the Genecept assay, a saliva-based genetic test to help clinicians make treatment decisions for patients with depression and other psychiatric disorders. </p> </td> <td> <p> Claritas Capital </p> </td> <td> <p> $5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Cardiac Dimensions </p> </td> <td> <p> WA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The Carillon system is designed to treat heart failure patients suffering from functional mitral regurgitation. </p> </td> <td> <p> MH Carnegie, Lumira Capital and others </p> </td> <td> <p> $20m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> InfoBionics </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring/digital health </p> </td> <td> <p> The cloud-based MoMe system is a remote patient monitoring device, initially focused on detecting cardiac arrhythmias. </p> </td> <td> <p> Safeguard Scientifics, Mass Medical Angels, Broadview Ventures, TiE, Beta Fund, Boardwalk, Launchpad Venture Group, Cherrystone TCA, HTC, Boynton, Keiretsualso </p> </td> <td> <p> $17m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Menix </p> </td> <td> <p> Lyon </p> </td> <td> <p> France </p> </td> <td> <p> Orthopedics/Dental </p> </td> <td> <p> Menix manufactures orthopedics and dental implants. </p> </td> <td> <p> Keensight Capital, LBO Partners, Turenne Inveestissement and others </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Sequent Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Neurology </p> </td> <td> <p> Squent is develloping catheter-based neurovascular technologies. It has two CE-marked devices: the WEB aneurysm embolization system and VIA microcatheter. </p> </td> <td> <p> Delphi Ventures, Domain Associates, US Venture PArtners, Versant Ventures </p> </td> <td> <p> $20m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Tendyne </p> </td> <td> <p> MN </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Tendyne is developing a retrievable, transcatheter mitral valve implantation system for treating mitral regurgitation. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $25m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Eventus Diagnostics </p> </td> <td> <p> FL </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The Octava breast cancer tests are immunoassays designed for adjunctive used with screening mammorgraphy to help identify false positive and false negative results. </p> </td> <td> <p> Private investors </p> </td> <td> <p> $2.72m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ForSight Vision5 </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> ForSight is developing devices to treat front-of-the-eye diseases such as glaucoma and dry eye disease. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $15m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Advanced Cardiac Therapeutics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> ACT is developing the next-generation of its TempaSure temperature-sensing radiofrequency ablation catheter for treating cardiac arrhythmias. </p> </td> <td> <p> New Enterprise Associates, NBGI Ventures, among others </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Guardant Health </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The Guardant 360 is a blood-based cancer teset for noninvasive real time tumor sequencing. </p> </td> <td> <p> Khosla Venture, Sequoia Capital, Pejman Mar Ventures </p> </td> <td> <p> $30m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> NeuMoDx </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The NeuMoDx 500 molecular IVD system integrates magentic particl affinity capature and real time PCR chemistry in a multisample microfluid cartridge. </p> </td> <td> <p> Pfizer Ventures, Baird Capital, Venture Investors, Arboretum Ventures, Wolverine Venture Fund </p> </td> <td> <p> $21m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Convergent Dental </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Dental surgical devices </p> </td> <td> <p> Convergent has developed Solea, the world's first-ever computer-aided CO2 laser to be US FDA-cleared for both hard and soft tissue procedures., </p> </td> <td> <p> Long River Ventures </p> </td> <td> <p> $8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> AdvanDx </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> AdvanDx develops rapid molecular diagnostic tests for infectious diseases. It has a CE marked CandidaQuickFIUSH test for identifying yeast from positive blood cultures, and is pending US FDA clearance for an MRSA test. </p> </td> <td> <p> Merck Global Health Innovation Fund, SLS Ventures, LD Pensions </p> </td> <td> <p> $12m </p> </td> <td> <p> Series B-1 </p> </td> <td> <p> $35m </p> </td> </tr> <tr> <td> <p> ProteoMedix </p> </td> <td> <p> Zurich </p> </td> <td> <p> Switzerland </p> </td> <td> <p> IVD </p> </td> <td> <p> ProteoMedix is developing a pretein test for aiding detection of prostate cancer. </p> </td> <td> <p> Altos Venture, Zurcher Kantonalbank and private investors </p> </td> <td> <p> $3.6m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Personal Genome Diagnostics </p> </td> <td> <p> MD </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> PGDx's circulating tumor DNA (ctDNA) assyas are based on the company's proprietary PARE technology which enables whole-genome identification of changes in tumor-specific ctDNA. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Integrated Diagnostics </p> </td> <td> <p> WA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Xpresys Lung is a proteomic lung cancer test, designed to identify whether lung nodules detected via diagnostic imaging are benign or not. </p> </td> <td> <p> Baird Capital, InterWest Partners, Wellcome Trust, Alexandria Venture Investments </p> </td> <td> <p> $30.25m </p> </td> <td> <p> Series B </p> </td> <td> <p> $60.25m </p> </td> </tr> <tr> <td> <p> Atlas Genetics </p> </td> <td> <p> Bath </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> The Atlas io system is a molecular diagnostic platform for the ultra-rapid diagnosis of infectious diseases including sexually transmitted infections and hospital acquired infections. </p> </td> <td> <p> Novartis Venture Funds, Consort Medical, Life Sciences Partners, BB Biotech VEntures, J&amp;J Development Corp, YFM Equity Partners and private investors </p> </td> <td> <p> &pound;16.9m </p> </td> <td> <p> Series B </p> </td> <td> <p> over &pound;21m </p> </td> </tr> <tr> <td> <p> Voluntis </p> </td> <td> <p> Paris </p> </td> <td> <p> France </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> Voluntis develops software to enable personalization of medical treatment and improve real-life outcomes. </p> </td> <td> <p> Bpifrance Large Venture, Innovation Capital, Vesalius Biocapital, Qualcomm Ventures, CapDecisif Management, CM-CIC Capital Innovation, Sham </p> </td> <td> <p> &euro;20.75m ($29m) </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Bjond </p> </td> <td> <p> OH </p> </td> <td> <p> US </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> BjondHealth offers healthcare providers workflow automation, decision support and behavioral economics to &quot;transform care management and drive behavior change among chronically ill and worried well people&quot;. </p> </td> <td> <p> Draper Triangle Ventures, TriStar Technology Ventures, Hopen Life Science Ventures </p> </td> <td> <p> $3.25m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Vapotherm </p> </td> <td> <p> NH </p> </td> <td> <p> US </p> </td> <td> <p> Respiratory therapy </p> </td> <td> <p> Vapotherm's high flow therapy supports patients in respiratory distress. It delivers medical grade vapor to the patient and offers precise temperature and oxygen control, in one integrated system. </p> </td> <td> <p> Gilde Healthcare Partners, Adage Capital Management, 3x5 Special Opportunity Fund, Morgenthaler Ventures, Kaiser Permanente, Integral Capital Partners, QuestMark Partners, Creek Capital </p> </td> <td> <p> $24m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Gordian Surgical </p> </td> <td> <p> Tel Aviv </p> </td> <td> <p> Israel </p> </td> <td> <p> Surgery </p> </td> <td> <p> Gordian's two-in-one trocar with a built-in closure device is used to open and suture abdominal incisions during laparscopic procedures. </p> </td> <td> <p> Trendlines Medical, angel and private investors </p> </td> <td> <p> $1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>MAY</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Enterome Bioscience </p> </td> <td> <p> Paris </p> </td> <td> <p> France </p> </td> <td> <p> IVD </p> </td> <td> <p> Enterome's Metagenotyping process identifies an individual gut microbiome profile and the information used for disease management and prevention. </p> </td> <td> <p> Seventure, Lundbeckfond Ventures, Omnes Capital </p> </td> <td> <p> &euro;10m </p> </td> <td> <p> Series B-1 </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Inspire Medical Systems </p> </td> <td> <p> MN </p> </td> <td> <p> US </p> </td> <td> <p> Respiratory disorder/neurology </p> </td> <td> <p> The US FDA-approved Inspire Upper Airway Stimulation therapy is a neurostimulation device for treating obstructive sleep apnea </p> </td> <td> <p> OrbiMed, J&amp;J, Aperture Venture Partners, Kleiner Perkins Caufield Byers, US Venture Partners, Synergy Life Science Partners, Medtronic, GDN Holding and TGap Ventures </p> </td> <td> <p> $40m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Keystone Heart </p> </td> <td> <p> Caesarea </p> </td> <td> <p> Israel </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The TriGuard is a CE-marked cerebral protection device designed to minimize the risk of cerebral damange during transcatheter aortic valve replacement and other cardiovascular procedures. </p> </td> <td> <p> Orbimed, Baize Investments </p> </td> <td> <p> $14m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> EndoGastric Solutions </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Gastroenterology </p> </td> <td> <p> The US FDA-cleared EsophyX is used to perform transoral incisionless fundoplication (TIF), a procedure for reconstructing the gastroesophageal valve to treat reflux. </p> </td> <td> <p> Advanced Technology VEntures, Canaan Partners, Chicago Growth Partners, De Novo Ventures, Foundation Medical PArtners, Oakwood Medical Investors and Radius Ventures </p> </td> <td> <p> $30m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Counsyl </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Counsyl overs breast cancer screening services for the BRCA1 and BRCA2 genes. </p> </td> <td> <p> Rosemont Seneca Technology Partners, Goldman Sachs Asset Management </p> </td> <td> <p> $28m </p> </td> <td> <p> Series D </p> </td> <td> <p> $93m </p> </td> </tr> <tr> <td> <p> Lophius Biosciences </p> </td> <td> <p> Regensburg </p> </td> <td> <p> Germany </p> </td> <td> <p> IVD </p> </td> <td> <p> Lophius develops T cell-based research tools and diagnostic systems for functional assessment of disease-reactive T cells. Its pipeline include T-Track CMV, T-Track TB and T-Track MS. </p> </td> <td> <p> VRD, SRefit,among others </p> </td> <td> <p> &euro;2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Ceterix Orthopaedics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Ceterix specialises in arthroscopy tools for treating soft tissue injuries in the joints </p> </td> <td> <p> Novo, Versant Ventures, 5AM Ventures </p> </td> <td> <p> $18m (including debt financing) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Medrobotics </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> The CE-marked Flex system is a robot-assisted flexible endoscopic platform for use during surgical procedures. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $26m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> SolveBio </p> </td> <td> <p> NY </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> SolveBio specialises in genomic data analysis. </p> </td> <td> <p> Andressen Horowitz, SV Angel, individual investors </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> iRhythm Technologies </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology/patient monitoring </p> </td> <td> <p> The Zio peel-and-stick heart monitor patch is used for monitoring arrhythmias in cardiac patients for up to a fortnight. </p> </td> <td> <p> NOvo, Norwest Venture PArtners </p> </td> <td> <p> $17m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Ascendant Dx </p> </td> <td> <p> AR </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> MelodyDx is a tears-based diagnostic test that detects proteins in human tears to differential malignant breast mass from benign tissue, </p> </td> <td> <p> Strategic and private investors </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Quantapore </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Quantapore is developing a nanopore-based sequencing technology for rapid, affordable and accurate sequencing of entire genomes. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $35m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> HistoSonics </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> Men's health </p> </td> <td> <p> Vortx Rx is desigend to take a 3D image of the prostate to allow urologists to target ultrasound energy to the disease area and break down access tissue relieving symptoms of benign prostate hyperplasia. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $14m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> JustRight Surgical </p> </td> <td> <p> CO </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> JustRight develops tissue-sealing devices for use in nminimallly invasive surgical procedures. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7.5m </p> </td> <td> <p> Undisclosed </p> </td> <td><p></td> </tr> <tr> <td> <p> ALung Technologies </p> </td> <td> <p> PI </p> </td> <td> <p> US </p> </td> <td> <p> Respiratory disorders </p> </td> <td> <p> The Hemolung respiratory assist system delivers Respiratory Dialysis, which is low-flow extracorporeal carbon dioxide removal. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Nuubo </p> </td> <td> <p> Madrid </p> </td> <td> <p> Spain </p> </td> <td> <p> Wearable medical technologies </p> </td> <td> <p> Nuubo's nECG dynamic platform allows remote, remote monitoring of patients' electrocardiogram signal that is being captured and transmitted via biomedical garments worn by the patient. </p> </td> <td> <p> Caixa InnvierteBioMed II, CRB Bio II </p> </td> <td> <p> &euro;3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Premia Spine </p> </td> <td> <p> Ramat Poleg </p> </td> <td> <p> Israel </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> The TOPS system is designed to treat and preserve spinal motion in patients with spinal problems </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> SISCAPA Assay Technologies </p> </td> <td> <p> DC </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The SISCAPA (stable isotope standards and caputre by anti-peptide antibodies) technology is used ofr measuring multiplexed protein panels in dried blood spots. </p> </td> <td> <p> Private investors </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>JUNE</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> InvisionHeart </p> </td> <td> <p> TN </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> InvisionHeart is developing a wireless electrocardiogram technology. </p> </td> <td> <p> TriStar Technology Ventures, Mountain Group Capital, NueCura Partners </p> </td> <td> <p> $1.9m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Senseonics </p> </td> <td> <p> MD </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Senseonics is developing a continuous glucose monitoring system that comprise an implantable glucose sensing chip and a wireless mobile platform. </p> </td> <td> <p> Anthem Capital, Delphi Ventures, Greenspring Associates, HealthCare Ventures, New Enterprise Associates and other strategic partners </p> <p></td> <td> <p> $20m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Cheetah Medical </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> The Cheetah Nicom hemodynamic management system is a noninvasive way of measuring key hemodynamic parameters in ICU patients and also in the operatin room and emergency department. The system is already commercialised in 60 countries including the US. </p> </td> <td> <p> HighCape Partners </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Part of larger $14m round </p> </td> </tr> <tr> <td> <p> Proteus Digital Health </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Smart digital medicines </p> </td> <td> <p> Proteus has CE-marked and received US FDA clearance for its wearable and ingestible Sensor devices that are integrated into medicines and allow digital health feedback and monitoring. </p> </td> <td> <p> Carlyle, Essex Woodlands, Kaiser PErmanente, MEdtronic, Novartis, Otsuka, ORacle, ON Semiconductor and other investors </p> </td> <td> <p> $120m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> QuantuMDx </p> </td> <td> <p> Newcastle </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> QuantMDx is developing the Q-POC, a handheld device to provide affordable, point-of-care DNA analysis and sequencing with results in minutes. </p> </td> <td> <p> Private investors </p> </td> <td> <p> $8.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $21m </p> </td> </tr> <tr> <td> <p> Transcatheter Technologies </p> </td> <td> <p> Regensburg </p> </td> <td> <p> Germany </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The Trinity transcatheter aortic valve implantation system is allows repositioning which then leads to better placement and eliminates paravalvular leaks. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Series B-2 </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Spinal Kinetics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> The M6 artifical disc is designed to treat patients with spinal degenerative disc disease, while preserving motion. </p> </td> <td> <p> Scale Venture, Lumira Capital, De Novo Ventures, SV Life Sciences, HLM Ventures </p> </td> <td> <p> $34m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> PowerVision </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The FluidVision accommodative intraocular lens, is in clinical trials. The implant claims to restore true accommodation and allows wearers to focus vision on near objects. </p> <p></td> <td> <p> Medtronic, Johnson &amp; Johnson, Venrock, Advanced Technology Ventures, Frazier Healthcare, Aisling Capital, Correlation Venture Partners </p> </td> <td> <p> $10m </p> </td> <td> <p> Series D2 </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Dune Medical Devices </p> </td> <td> <p> Caesarea </p> </td> <td> <p> Israel </p> </td> <td> <p> Oncology </p> </td> <td> <p> The US FDA-apprroved MarginProbe system enables real time detection of cancer at the surface of excised tissue specimens during surgery for breast cancer. </p> </td> <td> <p> The Kraft Group and Canepa Advanced Healthcare Fund, among others. </p> <p></td> <td> <p> $14m </p> </td> <td> <p> Part of a larger $21m financing </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> CURA Healthcare </p> </td> <td> <p> Chennai </p> </td> <td> <p> India </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> CURA specializes in mobile computed radiography systems for use in hospitals by the patient's bedside. </p> <p></td> <td> <p> Peepul Capital </p> </td> <td> <p> $6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Definiens </p> </td> <td> <p> Munich </p> </td> <td> <p> Germany </p> </td> <td> <p> IVD </p> </td> <td> <p> Definiens specializes in digital pathology image analysis, and is expanding into digital tissue-based diagnostics for oncology and immunotherapy. </p> </td> <td> <p> Wellington Partners, Gilde Healthcare, Cipio Partners and TVM Capital </p> </td> <td> <p> &euro;15m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> EndoShape </p> </td> <td> <p> CO </p> </td> <td> <p> US </p> </td> <td> <p> Peripheral vascular </p> </td> <td> <p> EndoShape's Medusa is a US FDA-cleared vascular plug used to repair vessels that rupture during peripheral vascular embolization, </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> MedGenome </p> </td> <td> <p> Kerala </p> </td> <td> <p> India </p> </td> <td> <p> IVD </p> </td> <td> <p> MedGenome specializes in next-generation sequencing. It provides sequencing and data analysis services to pharma companies and hospitals to help with disease risk assessment, management, treatment, and patient outcomes. </p> </td> <td> <p> Papillon Capital, Emerge Venture, and private investors </p> </td> <td> <p> $4m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed Undisclosed </p> </td> </tr> <tr> <td> <p> Chrono Therapeutics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Drug delivery </p> </td> <td> <p> Chrono is developing the SmartStop programmable transdermal drug delivery system and real-time behavioral support program for smoking cessation. </p> </td> <td> <p> Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, Mayo Clinic and GE Ventures . </p> </td> <td> <p> $32m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ZetrOZ </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Pain management </p> </td> <td> <p> ZetrOZ has developed SAM, a wearable device for delivering ultrasound therapy to relieve pain. </p> </td> <td> <p> Angel and private investors </p> </td> <td><p> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Benvenue Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> The Kiva VCF system is an implant-based technology for the minimally invasive vertebral augmentation to repair compression fractures </p> </td> <td> <p> InterWest PArtners, Versant Ventures, DeNovo Ventures, Domain Associates and Technology Partners </p> </td> <td> <p> $40m </p> </td> <td> <p> Series E </p></td> <td> <p> Over $100m </p> </td> </tr> <tr> <td> <p> Nucleix </p> </td> <td> <p> Tel Aviv </p> </td> <td> <p> Israel </p> </td> <td> <p> IVD </p> </td> <td> <p> The company's lead product is the urine-based Bladder EpiCheck for detecting bladder cancer </p> </td> <td> <p> Orbimed, private investors and others </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Courtagen </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Courtagen develops tests for mitochondrial disorders, epilepsy and seizure disorders, Autism Spectrum Disorder, and other conditions based on next-generation sequencing technology </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Mitralign </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Mitralign's system is designed for mitral valve repair </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Consano Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Consano is developing an intelligent monitoring device for detecting and managing sepsis in patients in intensive care units </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3.9m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>JULY</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Empire Genomics </p> </td> <td> <p> NY </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Empire has DNA tests for prostate cancer and multiple myeloma; its products are used in personalized medicine. </p> </td> <td> <p> Rand Capital, SCP Buffalo Incubator Innovate NY Fund </p> </td> <td> <p> $1m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Rotation Medical </p> </td> <td> <p> MN </p> </td> <td> <p> US </p> </td> <td> <p> Arthroscopy </p> </td> <td> <p> The Rotation Medical system consists of a bioindustive implant and proprietary surgical tools to repair rotator cuff injury. </p> </td> <td> <p> Life Sciences Partners, New Enterprise Associates, Pappas Ventures and others </p> </td> <td> <p> $27.2m </p> </td> <td> <p> Series B </p> </td> <td> <p> $47.2m </p> </td> </tr> <tr> <td> <p> electroCore </p> </td> <td> <p> NJ </p> </td> <td> <p> US </p> </td> <td> <p> Neurostimulation </p> </td> <td> <p> electroCore's gammaCore system is CE marked for noninvasive vagal nerve stimutlation to treate primary headache, bronchoconstruction, epilepsy, gastric motility disorders and depression and anxiety. </p> </td> <td> <p> Merck, Easton Capital, CoreVentures and founder </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $50m </p> </td> </tr> <tr> <td> <p> Cardiac Insight </p> </td> <td> <p> WA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology/Patient monitoring </p> </td> <td> <p> The Stealth Ambulatory Monitor is a Band-Aid-sized strip that is worn by the patient to monitor heartbeat and detect atrial fibrillation. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Gynesonics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Women's health </p> </td> <td> <p> The VizAblate is a minimally invasive device that uses ultrasound imaging and radiofrequency ablation to remove fibroid tumor from the uterus. </p> </td> <td> <p> HBM Partners, Correlation Ventures, Abingworth, Advaned Technology Ventures, InterWest Partners, among others </p> </td> <td> <p> $6.3m (including debt financing) </p> </td> <td> <p> Part of an expected $35.5m series D </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Veran Medical </p> </td> <td> <p> MO </p> </td> <td> <p> US </p> </td> <td> <p> Imaging </p> </td> <td> <p> Veran's SPiNDrive 2.0 is an electromagnetic airway mapping system. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6.5m </p> </td> <td> <p> Part of an expected $7.5m round </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Valeritas </p> </td> <td> <p> NJ </p> </td> <td> <p> US </p> </td> <td> <p> Diabetes management </p> </td> <td> <p> The V-Go is a disposable insulin dispenser for adult diabetics. </p> </td> <td> <p> Welsh, Carson, Anderson &amp; Stowe, MPM Capital, Pitango Venture Capital and Kaiser Permanente </p> </td> <td> <p> $22m </p> </td> <td> <p> Part of an expected $45m </p> </td> <td> <p> Undislcosed </p> </td> </tr> <tr> <td> <p> Sophia Genetics </p> </td> <td> <p> London </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> Sophia specialises in data-driven medicine, which combines next-generation sequencing with predictive algorithms to diagnose genetic diseases. </p> </td> <td> <p> Invoke Capital, Swisscom, Endeavor Vision </p> </td> <td> <p> $13.75m </p> </td> <td> <p> Series B </p> </td> <td> <p> $17m </p> </td> </tr> <tr> <td> <p> BioVentrix </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The CE-marked Revivent myocardial anchoring system is used in a less invasive surgical procedure to exclude heart tissue scarred by myocardial infarction, enabling the heart to work more efficiently. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $12.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Epic Sciences </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Epic is developing a circulating tumor cell analysis platform for monitoring and personlizing cancer treatments. </p> </td> <td> <p> RusanoMedInvest, Arcus Venturews, Domain Associates, Roche Venture Fund, Pfizer Venture Investments. </p> </td> <td> <p> $30m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Proteus Digital Health </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Digital medicine </p> </td> <td> <p> Proteus has CE marked and FDA cleared devices incorporating its wearable and Ingestible Sensor technology, to help improve effectiveness of existing pharmaceutical treatments. </p> </td> <td> <p> Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, ORacle, ON Semiconductor and others. </p> </td> <td> <p> $172m </p> </td> <td> <p> Second tranche series G </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> CyMedica Orthopedics </p> </td> <td> <p> AZ </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> CyMedica specializes in electrical muscle stimulation. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Augmenix </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Cancer management </p> </td> <td> <p> Augmenix's SpaceOAR hydrogel is used for protecting the rectum during prostate radiation therapy. </p> </td> <td> <p> ExcelestarVentures, CHV II, Catalyst Health Ventures, Sparta Group, other investors. </p> </td> <td> <p> $10.8m </p> </td> <td> <p> Series D </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> CardioDx </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The Corus CAD is a blood test to assess the likelihood of patient developing obstructive coronary artery disease, </p> </td> <td> <p> GE HEalthcare, Kleiner Perkins Caufield &amp; Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, Longitude Capital, JP Morgan, Acadia Woods PArtners, ARtiman Ventures, Bright Capital and Temasek. </p> </td> <td> <p> $21m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Trice Medical </p> </td> <td> <p> PA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> mi-eye is a disposable, single-use visualization device that uses a needle with an integrated camera and lightsource to perform a diagnostic arthroscopy. </p> </td> <td> <p> Safeguard Scientifics </p> </td> <td> <p> $11.6m </p> </td> <td> <p> First tranche of series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> SenGenix </p> </td> <td> <p> NC </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> SenGenix aims to improve point of care testing by developing specific molecular sensors for each analyte in its POC tests and keeping test strips and analyzer as simple and inexpensive as possible. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Emulate </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Emulate's Organs-on-Chips bioemulation products allows in vitro testing during the development of new pharmacuticals and personalized medicine products, among other things. </p> </td> <td> <p> NanoDimension, Cedards-Sinai Medical Center and private investor </p> </td> <td> <p> $12m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Neograft </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Neograft's AngioShield vein graft is a structural polymeric support layer surrounding the outside of a harvested vein - used in heart bypass procedures - that mechanically strengthens it against overdilation from arterial pressure, </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $11m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Edico Genome </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The Dragen Bio-IT processor is said to be the world's first next-generation sequencing bioinformatics appliation-specific integrated circuit. </p> </td> <td> <p> Qualcomm Ventures, Axon Ventures, private investor </p> </td> <td> <p> $10m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Metronom Health </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Metronom is developing continuous glucose monitoring systems. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $4.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Xagenic </p> </td> <td> <p> Toronto </p> </td> <td> <p> Canada </p> </td> <td> <p> IVD </p> </td> <td> <p> Zagenic is developing enzyme-free molecular diagnostics platform </p> </td> <td> <p> Domain Associates, CTI Life Sciences Fund, BDC Capital, Ontario Emerging Technologies Fund </p> </td> <td> <p> CA$25.5m </p> </td> <td> <p> Series B </p> </td> <td> <p> CA$35.5m </p> </td> </tr> <tr> <td> <p> OBMedical </p> </td> <td> <p> FL </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> OBMedical's LaborView monitor is a wireless electrode-based maternal-fetal system that monitors continuously labor contractions as well as the mother;s and baby's heart rates. </p> </td> <td> <p> Angel Investment </p> <p> Atlanta Technology Angels, Upstate Carolina Angel Network and the Palmetto Angel 214 Fund </p> </td> <td> <p> $2.1m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>AUGUST</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> LensAR </p> </td> <td> <p> FL </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> The LensAR laser system is a femtosecond cataract laser that is built specifically for refractive cataract surgery. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Castle Biosciences </p> </td> <td> <p> TX </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Castle is developing molecular diagnostics for cancer. Their products include DecisionDx-Melanoma to determine metastatic risk in patients with melanoma. </p> </td> <td> <p> HealthQuest Capital, Mountain Group Capital, Longfellow VEnture PArtners and others. </p> </td> <td> <p> $11.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Seventh Sense Biosystems </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> SSB has developed the touch activated phlebotomy (TAP) system which is a virtually painless blood collection and diagnostic platform that does not require blood to be drawn from the vein. </p> </td> <td> <p> SFS VC (venture capital unit of Siemens), Novartis, LabCorp, Flagship Ventures, Polaris Partners </p> </td> <td> <p> $16m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ViaCyte </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> ViaCyte is developing a cell-based therapy for diabetes. </p> </td> <td> <p> Undislcosed </p> </td> <td> <p> $5.4m </p> </td> <td> <p> Series C-1 </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Atonarp </p> </td> <td> <p> Tokyo </p> </td> <td> <p> Japan </p> </td> <td> <p> IVD </p> </td> <td> <p> Atonarp is developing its Smart Spectrometer technology platform for various industrial and healthcare applications. </p> </td> <td> <p> Walden Riverwood Ventures </p> </td> <td> <p> $8m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Advanced Catheter Technologies </p> </td> <td> <p> TN </p> </td> <td> <p> US </p> </td> <td> <p> Cardiovascular </p> </td> <td> <p> ACT specializes in developing innovative catheter technologies for treating vascular disease. Its lead product is the Occlusion Perfusion Catheter for targeted endovascular drug delivery. </p> </td> <td> <p> ACT I Investments, Chattanooga Renaissance Fund, Maclellan Foundation, Innova Fund II, INCITE CoInvestment Fund, DeMoss Alternative Opportunities Fund, Blank Slate Venture Fund II </p> </td> <td> <p> $3m </p> </td> <td> <p> Series B-1 </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Silk Road Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Neurovascular </p> </td> <td> <p> The Silk Road system is a transcarotid stent system used during carotid artery stenting in stroke patients, to make the procedure safer by temporarily reversing the blood flow away from the brain and preventing blockages from emboli. </p> </td> <td> <p> Warburg Pincus, The Vertical Group, among others </p> </td> <td> <p> $15m </p> </td> <td> <p> Undisclosed; first tranche of a larger $22m round </p> </td> <td> <p> over $50m </p> </td> </tr> <tr> <td> <p> Advanced Cooling Therapy </p> </td> <td> <p> IL </p> </td> <td> <p> US </p> </td> <td> <p> Critical care </p> </td> <td> <p> ACT's Esophageal Cooling Device is designed to be inserted into the esophagus to modulate and control patient temperature in teh operating room, recovery room, ICU and emergency room. </p> </td> <td> <p> Heartland Angels, Gopher Angels, TWB Investment Partnership and others </p> </td> <td> <p> $1.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Claret Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiac surgery /Neurology </p> </td> <td> <p> Claret's Sentinel cerebral protection system is a filter that captures and removes emboli released during transcatehter aortic valve replacement procedures. </p> </td> <td> <p> Sante Ventures, Lightstone Ventures, Easton Capital. </p> </td> <td> <p> $18m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Surgical Frontiers </p> </td> <td> <p> UT </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Surgical Frontiers incubates start-up companies developing surgical technologies for the musculoskeletal markets. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Healthsense </p> </td> <td> <p> MA and MN </p> </td> <td> <p> US </p> </td> <td> <p> Remote patient monitoring </p> </td> <td> <p> Healthsense develops remote monitoring solutions to improve outcomes for those with chronic health conditions </p> </td> <td> <p> Mansa Capital, Merck Global Health Innovation Fund, Radius Ventures </p> </td> <td> <p> $10m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>SEPTEMBER</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Harpoon Medical </p> </td> <td> <p> MD </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Harpoon is developing a beating heart mitral valve repair technology. </p> </td> <td> <p> Epidarex Capital </p> </td> <td> <p> $3.75m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Avelas Biosciences </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> The Avelas Cancer Illuminator uses increased activity of proteases in tumors and metastases as a cancer marker. It's first candidate is a test for breast cancer surgery patients. </p> </td> <td> <p> Avalon Ventures, Torrey Pines Investment, WuXi PharmaTech Investments and other investors </p> </td> <td> <p> $7.4m </p> </td> <td> <p> Series B </p> </td> <td> <p> $14.7m </p> </td> </tr> <tr> <td> <p> Tryton Medical </p> </td> <td> <p> NC </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Tryton is developing coronary stents for bifurcated lesions. </p> </td> <td> <p> RiverVest Venture Partners, 3x5 Specilal Opportunity Fund, Canepa Advanced Healthcare Fund and other investors </p> </td> <td> <p> $20m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> eNeura </p> </td> <td> <p> MD </p> </td> <td> <p> US </p> </td> <td> <p> Neurostimulation </p> </td> <td> <p> eNeura has an FDA-approved transcranial magnetic stimulation device for treating migraine. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Fractyl Labs </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Diabetes management </p> </td> <td> <p> Fractyl has developed developed the Revita DMR system to perform an endoscopic procedure which remodels the duodenal mucosa with thermal ablation to improve glycemic control for Type 2 diabetes patients. </p> </td> <td> <p> Mithril Captial Management, General Catalyst Partners, Bessemer Venture PArtners and Domain Ventures </p> </td> <td> <p> $40m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Biocartis </p> </td> <td> <p> Mechelen </p> </td> <td> <p> Belgium </p> </td> <td> <p> IVD </p> </td> <td> <p> Biocartis has just launched its Idylla miniaturized automated molecular diagnostic system. The first test that has been CE marked to run on the system is a BRAF mutation test. </p> </td> <td> <p> Johnson &amp; Johnoson, Hitachi Chemical, PMV Tina Fund and other investors </p> </td> <td> <p> &euro;64.5m ($85m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> &euro;240m ($316m) </p> </td> </tr> <tr> <td> <p> Propellor Health </p> </td> <td> <p> WI and PA </p> </td> <td> <p> US </p> </td> <td> <p> Respiratory disease </p> </td> <td> <p> Propellor provides digital solutions that combine sensors, mobile apps and predictive analytics to help patients with respiratory diseases and improve therapy adherence and self management. </p> </td> <td> <p> Safeguard Scientfics, The Social+Capital PArtnership </p> </td> <td> <p> $14.5m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> InSightec </p> </td> <td> <p> Tirat Carmel </p> </td> <td> <p> Israel </p> </td> <td> <p> Therapeutic ultrasound </p> </td> <td> <p> InSightec offers MR-guided focused ultrasound therapy for the noninvasive treatement of various clinical indications, including neurosurgery, oncology and gynaecology. </p> </td> <td> <p> Shanghai GEOC Hengtong Investment Ltd Partnership, York Capital Management, and others </p> </td> <td> <p> $12.5m </p> </td> <td> <p> Part of a $50m series D </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Tissue Regeneration Systems </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> TRS is using 3D printing technology to develop porous bioresorbable scaffolding for reconstructing skeletal defects. </p> </td> <td> <p> Venture Investors, the University of Michigan, the Michigan Economic Development Corp and Wisconsin Alumni Research Foundation and others </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Avinger </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Peripheral vascular </p> </td> <td> <p> Avinger's lumivascular approachr treating peripheral artery disease entails an interventional catheter with a light-based, radiation-free intravascular imaging technology. It provides physicians with live, real-time images of the inside of the artery during treatment. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $34.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Intrinsic Therapeutics </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Intrinsic develops devices for treating lumbar disc herniation. </p> </td> <td> <p> New Enterprise Associates, New Leaf Venture Partners, Spray Venture Partners </p> </td> <td> <p> $17.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Ivantis </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Ivantis' Hydrus microstent is used to lower eye pressure for glaucoma patients. </p> </td> <td> <p> Foresite Capital, New Enterprise Associates, Delphi Ventures, Ascension Health Ventures, EDBI, GBS Ventures, Vertex Ventures and Memorial Care Innovation Fund, EDBI </p> </td> <td> <p> $25m </p> </td> <td> <p> Part of $71m Series B </p> </td> <td> <p> $88m </p> </td> </tr> <tr> <td> <p> Jiff </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Health IT </p> </td> <td> <p> Jiff provides a software platform that allows self-insured employers to connect to and manage hundreeds of digital health tools and provide each employee with an individualized health incentives program. </p> </td> <td> <p> Venrock, Aberdare Ventures, Aeris Capital </p> </td> <td> <p> $18m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Videregen </p> </td> <td> <p> Liverpool </p> </td> <td> <p> UK </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> Videregen uses decellularized organ scaffolds seeded with the patient's own cells to create bespoke organ replacements for organ transplantation. </p> </td> <td> <p> SPARK Impact, London Business Angels and others </p> </td> <td> <p> &pound;1.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Zyga Technology </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Zyga develops products for minimally-invasive lumbar spine surgery </p> </td> <td> <p> Versant Ventures, Split Rock PArtners, Domain Associates, MB Venture Partners </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Minerva Surgical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Women's health </p> </td> <td> <p> The Aurora endometrial ablation system is used to treat menorrhagia, abnormally heavy menstrual bleeding. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $25m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Inivata </p> </td> <td> <p> Cambridge </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> Inivata is developing a circulating tumor DNA analysis platform, with the potential to help doctors better monitor cancer patients and offer more personalized therapy. </p> </td> <td> <p> Imperial Innovations, Cambridge Innovation Capital, Johnson &amp; Johnson Development </p> </td> <td> <p> &pound;4m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Nanovi </p> </td> <td> <p> Copenhagen </p> </td> <td> <p> Denmark </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Nanovi's BioXmark is an injectable liquid tissue marker which forms a large 3D semi-solid gel once injected, to produce a high contrast marker that can be used with high precision imaging techniques to improve accuracy of radiotherapy. </p> </td> <td> <p> SEED Capital, Vaekstfonden and others </p> </td> <td> <p> &euro;2.7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Palmaz Scientific </p> </td> <td> <p> TX </p> </td> <td> <p> US </p> </td> <td> <p> Interventional cardiology </p> </td> <td> <p> Palmaz is developing stents based on a nanotechnology platform. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Around $26m </p> </td> </tr> <tr> <td> <p> COTA </p> </td> <td> <p> NJ </p> </td> <td> <p> US </p> </td> <td> <p> Health IT </p> </td> <td> <p> COTA (Cancer Outcomes Tracking and Analysis) is cloud-based platform that provides real-time clinical outcomes data and cost analysis for cancer care </p> </td> <td> <p> Horizon Healthcare Services, Med-Metrix </p> </td> <td> <p> $3.7m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> SeqLL </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> SeqLL offers direct RNA sequencing, RNA-Seq and data analysis and DNA sequencing services on the Helicos single-molecular sequencing technology. </p> </td> <td> <p> Genomic Diagnostic Technologies </p> </td> <td> <p> $1m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undislcosed </p> </td> </tr> <tr> <td> <p> Xinrong Best Medical Instrument </p> </td> <td> <p> Jiangsu </p> </td> <td> <p> China </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Xinrong manufactures orthopedic surgical instruments </p> </td> <td> <p> The Blackstone Group and private investors </p> </td> <td> <p> $100m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Cognoptix </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Cognoptix is developing an eye test that detects beta-amyloid signatures in the lens to diagnose Alzheimer's. </p> </td> <td> <p> Alopexx, Inventages, Launchpad Venture Group </p> </td> <td> <p> $15m </p> </td> <td> <p> Series D </p> </td> <td> <p> $32m </p> </td> </tr> <tr> <td> <p> <b>OCTOBER</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Intelligent Ultrasound </p> </td> <td> <p> Oxford </p> </td> <td> <p> UK </p> </td> <td> <p> Diagnostic imaging </p> </td> <td> <p> Intelligent Ultrasound offers software and imaging analytics to allow clinicians to provide better and more bespoke ultrasound imaging services to their patients. </p> </td> <td> <p> IP Group, IP Venture fund and angel investors </p> </td> <td> <p> &pound;1.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> NantHealth </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> NantHealth is developing a cloud-based single healthcare mangement platform that provides patient's genomic and proteomic data for improved treatment decision-making. </p> </td> <td> <p> Kuwait Investment Authority, Verizon, Celgene, Blackberry, Blackstone </p> </td> <td> <p> $250m </p> </td> <td> <p> Part of a $320m Series B round </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Syncardia </p> </td> <td> <p> AZ </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> CardioWest is the only US FDA-approved total artificial heart system that acts as a bridge for patients awaiting heart transplant surgery, </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6.4m </p> </td> <td> <p> Part of series F round </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Ischemia Care </p> </td> <td> <p> OH </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Ischemia Care has developed a blood test, ISCDX, which uses gene expression profiles to distinguish the different types of sotrke and where they originate. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.9m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Invitae </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Healthcare IT/bioinformatics </p> </td> <td> <p> Invitae is a genetic information company that aggregates the world's genetic tests and puts it onto a single data management infrastructure. </p> </td> <td> <p> The Broe Group, Decheng Capital, Deerfield Management, OrbiMed, Perceptive Advisors, Rock Springs Capital, Welington Management Company, Casdin Capital, Genesys Capital, Genomic HEalth, Randy Scott, Redmile Group. Thomas McNerney Partners </p> </td> <td> <p> $120m </p> </td> <td> <p> Series F </p> </td> <td> <p> $207m </p> </td> </tr> <tr> <td> <p> C2 Therapeutics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Minimally invasive surgery </p> </td> <td> <p> The Coldplay focal cryoballoon ablation system is designed to treat Barrett's esophagus via balloon catheter-enabled cryoablation. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $11.6m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $23m </p> </td> </tr> <tr> <td> <p> Thync </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Wearable tech/neurology </p> </td> <td> <p> Thync is developing the first lifestyle wearable that uses neurosignaling algorithms to shift and optomize people's state of mind. </p> </td> <td> <p> Kosla Ventures and others </p> </td> <td> <p> $13m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> TELABio </p> </td> <td> <p> PA </p> </td> <td> <p> US </p> </td> <td> <p> Regenerative medicine </p> </td> <td> <p> TELABio is in stealth mode but it is likely in the area of tissue regeneration products in orthopedics, based on the industry experience of its executives and directors. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $45.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Acutus Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Acutus is developing a 3D cardiacmapping system to identify heart arrhythmias. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $26.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Embo Medical </p> </td> <td> <p> Galway </p> </td> <td> <p> Ireland </p> </td> <td> <p> Peripheral vascular/oncology </p> </td> <td> <p> Embo is developing a minimally invasive vascular embolization device for treating variety of conditions including cancers, internal hemorrhage, aneurysms and venous diseases. </p> </td> <td> <p> AIB Seed Capital Fund, Irrus Investements, Medtech Business Angel Syndicate, Western Development COmmission, Enterprise Ireland, AIB Start-Up Accelerator Fund </p> </td> <td> <p> &euro;3m </p> </td> <td> <p> Seed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Sinopsys Surgical </p> </td> <td> <p> CO </p> </td> <td> <p> US </p> </td> <td> <p> ENT </p> </td> <td> <p> Sinopsys has developed a technique in which a lacrimal stent is used to divert eye drops from the tear duct into the sinuses to treat chronic sinusitis. </p> </td> <td> <p> High Country Venture and MercuryFund and others </p> </td> <td> <p> $8.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> MID Labs </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> MID develops tools used in vitreoretinal surgery. </p> </td> <td> <p> Orbimed, Frontline BioVentures, Softbank China Venture Capital, Allen Chao, Sungent BioVenture </p> </td> <td> <p> $51m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> GT Urological </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> Men's health </p> </td> <td> <p> The Phenix artifical urinary sphincter is designed to treat moderate to severe male stress urinary incontinence. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $16m </p> </td> </tr> <tr> <td> <p> Adarza Biosystems </p> </td> <td> <p> NY </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Adarza has developed a label-free, multiplex biosensor platform based on its Arrayed Imaging Reflectometry technology. It can rapidly identify and quantifiy several biological target analytes in a fluid sample without the use of chemical labels. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6.8m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Mimetas </p> </td> <td> <p> Leiden </p> </td> <td> <p> The Netherlands </p> </td> <td> <p> Drug development tools </p> </td> <td> <p> Mimetes develops organ-on-a-chip technologies for 3D disease and tissue-modelling in drug research. </p> </td> <td> <p> Zeeuws Investerings Fonds, Participatiemaatschapij Oost Nederland and others </p> </td> <td> <p> $5.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Cardiac Dimensions </p> </td> <td> <p> WA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The Carillon mitral contour system isan implantable device for reducing mitral annulus dilatation and thus reducing functional mitral regurgitation. </p> </td> <td> <p> Arboretum Ventures, MH Carnegie, Lumira Capital and others </p> </td> <td> <p> $8.5m </p> </td> <td> <p> Part of a $28.5m round </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Sequenta </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Sequenta is developing the ClonoSIGHT minimal residual disease test, based on its LymphoSIGHT platform, that can help in treatment decision making for patients with lymphoid cancers. </p> </td> <td> <p> Celgene and others </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ZipLine Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> ZipLine has developed the Zip surgical skin closure device. </p> </td> <td> <p> China Materialia, RA CApital MAnagement, Claremont Creek Ventures, XSeed Capital and others </p> </td> <td> <p> $5.7m </p> </td> <td> <p> Part of a larger series C round </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Medrobotics </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> Medrobotics specialize in computer-assisted robotic systems used in minimally invasive surgery. Its Flex system and Flex Retractor are CE-marked. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $20m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Enigma Diagnostics </p> </td> <td> <p> Salisbury </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> The CE-marked Enigma ML system is designed for quick, sensitive real-time PCR analysis. </p> </td> <td> <p> Shanghai Debay Capital and others </p> </td> <td> <p> $50m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Telcare </p> </td> <td> <p> ML </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Telcare has developed a mobile glucose monitoring platform. </p> </td> <td> <p> Norwest venture Partners, Sequoia, Qualcomm </p> </td> <td> <p> $32.5m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Gauss Surgical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Critical care </p> </td> <td> <p> The US FDA-cleared Triton mobile-based system is designed for intraoperative blood management. It provides real-time estimation of surgical blood loss on surgical sponges. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Gamma Medica </p> </td> <td> <p> NH </p> </td> <td> <p> US </p> </td> <td> <p> Imaging </p> </td> <td> <p> The FDA-approved fully digital LumaGEM molecular breast imaging system is designed to allow early breast cancer detection. </p> </td> <td> <p> Psilos Group </p> </td> <td> <p> $5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Somalogic </p> </td> <td> <p> CO </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Proteomics specialist Somalogic is leveraging its Slow Off-rate Modified Aptamer (SOMAmer) technology to develop clinical diagnostic products. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $16.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Sympara Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Neurostimulation </p> </td> <td> <p> Sympara is a stealth mode firm developing a neurostimulation device for reducing hypertension. </p> </td> <td> <p> Longitude Capital, among others </p> </td> <td> <p> $5.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Implandata Ophthalmic Products </p> </td> <td> <p> Hannover </p> </td> <td> <p> Germany </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> Implandata is developing an intraocular sensor that is used for continuous monitoring of the intraocular pressure in glaucoma patients. </p> </td> <td> <p> Born2Grow Venture Partners, Peppermint Charite Beteiligungsfonds, Hannover Beteiligungsfonds, High-Tech Grunderfonds, KfW and business angels </p> </td> <td> <p> &euro;3m </p> </td> <td> <p> Series B </p> </td> <td> <p> &euro;6m </p> </td> </tr> <tr> <td> <p> Cambridge Epigenetix </p> </td> <td> <p> Cambridge </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> Cambridge Epigenetix develops epigenetics tools, using a method called oxidative bisulfite sequencing (ox-BS sequencing). </p> </td> <td> <p> New Science Ventures, Syncona Partners, Cambridge Enterprise </p> </td> <td> <p> $5.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> InSilixa </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Stealth mode InSilixa InSilixa is building next generation, high-performance CMOS biochips for microarray technology, qPCR, and DNA sequencing. Its first products are focused on high multiplexed genomic tests for point of care detection of infectious diseases. </p> </td> <td> <p> PointGuard Ventures, Morningside </p> </td> <td> <p> $13m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Magic Leap </p> </td> <td> <p> FL </p> </td> <td> <p> US </p> </td> <td> <p> Visual display technology </p> </td> <td> <p> Magic Leap is a stealth mode company developing visual display technologies. ITs first product is a mobile and wearable eye device - with comparisons made with Google Glass - that is said to allow people to see virtual 3D objects as if they were part of the real world. </p> </td> <td> <p> Google, Qualcomm, Legendary Enterntainment, KKR, Vulcan, Kleiner Perkins Caufield &amp; Byers, Andreessen Horowitz, Obvious Ventures </p> </td> <td> <p> $542m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>NOVEMBER</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> <a href="http://www.clinica.co.uk/marketsector/Series-C-No-siree-as-Quanta-takes-initial-steps-towards-IPO-354972?autnID=/contentstore/clinica/codex/a6d23a5d-69c0-11e4-bed5-63485ace4170.xml">Quanta Fluid Solutions</a> </p> </td> <td> <p> Alcester </p> </td> <td> <p> UK </p> </td> <td> <p> Haemodialysis </p> </td> <td> <p> Quanta's SC+ is a compact, portable haemodialysis system that can be used in clinics and in patients' homes. </p> </td> <td> <p> ALIAD, Seventure PArtners, Wellington Partners, Seroba Kernal, NBGI Ventures, b-to-v Partners, IMI </p> </td> <td> <p> &pound;27m </p> </td> <td> <p> Series B </p> </td> <td> <p> over &pound;36m </p> </td> </tr> <tr> <td> <p> Humedics </p> </td> <td> <p> Berlin </p> </td> <td> <p> Germany </p> </td> <td> <p> IVD </p> </td> <td> <p> The LiMAx test allows for the quantitative measurement of an individual's liver function capacity within minutes, The test involves the FLIP diagnostic device, breath masks and a diagnostic drug. </p> </td> <td> <p> Peppermint VenturePartners, VC Fonds Technologie, ERP Startfonds, Ventegis, High-Tech Grunderfonds </p> </td> <td> <p> &euro;6.3m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> MyTomorrows </p> </td> <td> <p> Amsterdam </p> </td> <td> <p> The Netherlands </p> </td> <td> <p> Health IT </p> </td> <td> <p> MyTomorrows is an online platform that facilitates patient access to experimental treatments. </p> </td> <td> <p> Sofinnova Partners, Balderton Capital </p> </td> <td> <p> &euro;4.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Prostate Management Diagnostics </p> </td> <td> <p> WA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Prostate Management is developing molecular diagnostic tests for the diagnosis and prognosis of prostate cancer. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $1.1m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Vascular Dynamics </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Neurostimulation </p> </td> <td> <p> The MobiusHD implant is designed to stimulate the carotid sinus to help reduce high blood pressure. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $9.7m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> OrthAlign </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> OrthAlign specialises in precision alignment technology for use in total knee implant surgery and total hip arthroplasty. </p> </td> <td> <p> River Cities Capital Funds, Mutual Capital Partners, California Technology Ventures, Research Corporation Technologies , Okapi Venture Capital </p> </td> <td> <p> $15m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Over $20m </p> </td> </tr> <tr> <td> <p> Monteris Medical </p> </td> <td> <p> MN </p> </td> <td> <p> US </p> </td> <td> <p> Oncology </p> </td> <td> <p> Monteris develops minimally invasive laser system for ablating pathologic brain lesions, such as primary, metastatic lesions </p> </td> <td> <p> Birchview Capital, The Vertical Group, BDC Capital Healthcare Fund </p> </td> <td> <p> $30m </p> </td> <td> <p> Series B (split into two tranches; 2nd tranch closing March 2015) </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> JenaValve </p> </td> <td> <p> Munich </p> </td> <td> <p> Germany </p> </td> <td> <p> Cardiology </p> </td> <td> <p> JenaValve is developing transcatheter aortic valve implant technologies. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $10.9m </p> </td> <td> <p> Part of a $62.5m Series C round </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Helomics (previously Precision Therapeutics) </p> </td> <td> <p> PA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Helomics is ChemoFx chemoresponse marker is a diagnostic for allowing personalized treatment of women with gynelogic cancers. </p> </td> <td> <p> HealthCare Royalty PArtners </p> </td> <td> <p> $60m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Curetis </p> </td> <td> <p> Holzgerlingen </p> </td> <td> <p> Germany </p> </td> <td> <p> IVD </p> </td> <td> <p> Curetis develops infectious disease test panels to run on its Unyvero system. It has two CE marked tests: one for pneumonia testing and the other for implant and tissue infections. </p> </td> <td> <p> Qiagen, LSP HEalth Economics Fund, aeris Capital, BioMed Invest, CD Venture, Forbion Capital, HBM Partners, Life Sciences Partners, Roche Venture Fund, private investors </p> </td> <td> <p> &euro;14.5m </p> </td> <td> <p> part of a larger series B financing </p> </td> <td> <p> &euro;63.5m </p> </td> </tr> <tr> <td> <p> InfoBionic </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> The MoMe system is a cloud-based remote patient monitoring platform designed to detect cardiac arrhythmia. </p> </td> <td> <p> Excel Venture Management, Zaffre Investments, Safeguard Scientifics, Mass Medical Angels, BRoadview Ventures, The Indus Entrepreneurs, Beta Fund, Launchpad Venture Group, Cherrystone TCA, HTC, Boynton and Keiretsu </p> </td> <td> <p> $17m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> iHear Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> ENT </p> </td> <td> <p> iHear is developing a range of affordable hearing aids. </p> </td> <td> <p> Lighthouse Capital, Brother Industries, Ameritas </p> </td> <td> <p> $5m </p> </td> <td> <p> Series C </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Vivify Health </p> </td> <td> <p> TX </p> </td> <td> <p> US </p> </td> <td> <p> Patient monitoring </p> </td> <td> <p> Vivify is developing a mobile remote patient healthcare platform. </p> </td> <td> <p> LabCorp, Envision Healthcare, Heritage Group, Ascension Health Ventures </p> </td> <td> <p> $15m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undislcosed </p> </td> </tr> <tr> <td> <p> Iowa Approach </p> </td> <td> <p> IA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Iowa is developing catheter-based systems for treating atrial fibrillation. </p> </td> <td> <p> Boston Scientific, among others </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Genomics </p> </td> <td> <p> Oxford </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> Genomics has developed a platform for genomic sequence data analysis and interpretation. </p> </td> <td> <p> IP Group, among others </p> </td> <td> <p> &pound;10.3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> <b>DECEMBER</b> </p> </td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> <td><p></td> </tr> <tr> <td> <p> Xeltis </p> </td> <td> <p> Zurich </p> </td> <td> <p> Switzerland </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Xeltis is developing synthetic biodegradable heart valves and blood vessels. </p> </td> <td> <p> Life Sciences Partners, Amsterdam, Kurma Partners, VI Partners, Zug, among others </p> </td> <td> <p> &euro;27m ($34m) </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Interrad Medical </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> Surgery </p> </td> <td> <p> Interrad has developed SecurAcath, a device that anchors catheters in place. </p> </td> <td> <p> Wales Life Sciences Investment Fund, RBC Wealth Management Group, Lesmoir-Gordon, Boyle and Co, private investors </p> </td> <td> <p> $7.5m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $17.5m </p> </td> </tr> <tr> <td> <p> Conventus Orthopaedics </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Conventus develops self-expanding extremities implants for treating fractures within bones. </p> </td> <td> <p> Deerfield Management, Ally Bridge Group, Sightline Partners, Spray Fund, Blue Stem Capital, BioStar Ventures and Blue Sky Fund </p> </td> <td> <p> $24m </p> </td> <td> <p> AA </p> </td> <td> <p> $24m (plus $10m debt financing) </p> </td> </tr> <tr> <td> <p> Congenica </p> </td> <td> <p> Cambridge </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> Congenica's Sapientia is a modular and scalable data analytics tool for annotating and clinically interpreting genomic sequence data. </p> </td> <td> <p> Cambridge Innovation Capital </p> </td> <td> <p> &pound;1m </p> </td> <td> <p> Seed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Direct Flow Medical </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Direct Flow specializes in transcatehter aortic valve replacement systems. </p> </td> <td> <p> SV Life Sciences, among others </p> </td> <td> <p> $17m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> CardioKinetix </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Cardiology </p> </td> <td> <p> The Parachute ventricular partitioning device helps treat heart failure patients by separating the damanged heart tissue from the healthy. The device is in US pivotal trial for premarket approval. </p> </td> <td> <p> Edwards Lifesciences, US Venture Partners, Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), SV Life Sciences, Panorama Capital, New Leaf Venture Partners, and Lexington Private Equity </p> <p></td> <td> <p> $50m (plus exclusive option for Edwards to acquire) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Exco InTouch </p> </td> <td> <p> Nottingham </p> </td> <td> <p> UK </p> </td> <td> <p> Healthcare IT </p> </td> <td> <p> Exco provides mobile and digital services to pharmaceutical companies for the engagement and collection of information from patients in clinical trials and real-life settings. </p> </td> <td> <p> Albion Ventures , Scottish Equity Partners </p> </td> <td> <p> &pound;3.2m ($5.1m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Novacyt </p> </td> <td> <p> Paris </p> </td> <td> <p> France </p> </td> <td> <p> IVD </p> </td> <td> <p> Novacyt is commercialising its cytology-based cancer diagnostics. </p> </td> <td> <p> Alto Invest and others </p> </td> <td> <p> &euro;3.1m ($3.8m) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Bacterioscan </p> </td> <td> <p> MI </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> BacterioScan's Model 216Dx provides rapid detection of urinary tract infections. </p> </td> <td> <p> Warson Capital Partners, the Missouri Technology Corporation and BioGenerator Fund </p> </td> <td> <p> $6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Zyga Technology </p> </td> <td> <p> MN </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> The Glyder facet resurfacing system is designed to treat chronic back pain. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> EpiBone </p> </td> <td> <p> NY </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> EpiBone uses a scan of the patient's bone and their stem cells to construct and cultivate a defect-specific bone implant. </p> </td> <td> <p> NetScientific, among others </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Vimecom </p> </td> <td> <p> Tübingen </p> </td> <td> <p> Germany </p> </td> <td> <p> Cardiology </p> </td> <td> <p> Vimecom develops laser catheters that allow for pointed, linear and circular ablation for treating atrial fibrillation </p> </td> <td> <p> SHS Gesellschaft für Beteiligungsmanagement,S-VC, NRW.Bank, KfW, DSA Invest and private investors </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Protagen </p> </td> <td> <p> Dortmund </p> </td> <td> <p> Germany </p> </td> <td> <p> IVD </p> </td> <td> <p> Protagen develops tests and companion diagnostic products for use in the autoimmune field. </p> </td> <td> <p> Qiagen, MIG Fonds, Munich, NRW.BANK, Düsseldorf, and private investors </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> First of a two-tranche &euro;10m round </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> 14M Genomics </p> </td> <td> <p> Cambridge </p> </td> <td> <p> UK </p> </td> <td> <p> IVD </p> </td> <td> <p> 14MG is developing a clinical genomic data resource for cancer diagnostic and treatment applications, using gene sequencing technology and bioinformatics software licensed from the Sanger Institute. </p> </td> <td> <p> Syncona Partners </p> </td> <td> <p> &pound;12.5m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Image Stream Medical </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Imaging </p> </td> <td> <p> Image Stream Medical specializes in image management technonlogy used in various surgeries </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> InSightec </p> </td> <td> <p> Tirat Carmel </p> </td> <td> <p> Israel </p> </td> <td> <p> Therapeutic ultrasound </p> </td> <td> <p> InSightec offers MR-guided focused ultrasound therapy for the noninvasive treatement of various clinical indications, including neurosurgery, oncology and gynaecology </p> </td> <td> <p> Shanghai GEOC Hengtong Investment Ltd Partnership, York Capital Management, and others </p> <p></td> <td> <p> $59m </p> </td> <td> <p> Series D (completionof round; first tranche in Sept) </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Flower Orthopedics </p> </td> <td> <p> PA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Flower Orthopedics is the developer of FlowerCube &mdash; a kits containing all of the implants and instruments needed for bone-fixation procedures. All instruments in the kit are for single use and are disposable. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $2.2m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ForSight Vision6 </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Ophthalmology </p> </td> <td> <p> ForSight Vision6 is the 6th company to emerge from the incubator ForSight Labs.It is in stealthy mode. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $3m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Wright Therapy Products </p> </td> <td> <p> PA </p> </td> <td> <p> US </p> </td> <td> <p> Vascular </p> </td> <td> <p> Wright is a provider of compression therapy products. </p> </td> <td> <p> Pittsburgh Equity Partners and BlueTree Capital Partners and private investors </p> </td> <td> <p> $4.4m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Cotera </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Cotera is developing implantable devices for treating knee osteoarthritis </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $7.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> ImmusanT </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> ImmusanT is developing Nexvax2, an immunotherapy for Celiac disease, as well as the companion diagnostic for the therapy. </p> </td> <td> <p> Vatera Healthcare Partners </p> </td> <td> <p> $12m </p> </td> <td> <p> Series B </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Kew Group </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Kew offers genomic testing services. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $16.8m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> CardioDx </p> </td> <td> <p> CA </p> </td> <td> <p> US </p> </td> <td> <p> IVD </p> </td> <td> <p> Corus CAD is a blood test to measure the likelihood of obstructive coronary artery disease in symptomatic patients </p> </td> <td> <p> GE HEalthcare, Kleiner Perkins Caufield &amp; Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, Longitude Capital, JP Morgan, Acadia Woods PArtners, ARtiman Ventures, Bright Capital and Temasek. Alberta Investment Management Corporation </p> </td> <td> <p> $35m </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Sonoma Orthopedic Products </p> </td> <td> <p> IL </p> </td> <td> <p> US </p> </td> <td> <p> Orthopedics </p> </td> <td> <p> Sonoma develops orthopedic implants for wrist, ankle, and collarbone fractures </p> </td> <td> <p> First Analysis, Ascension Health Ventures, Split Rock Partners, Legacy Life Sciences, EDF Ventures, MedVenture Associates, DFJ InCube Ventures, Emergent Medical Partners, and Asset Management Partners </p> </td> <td> <p> $12m </p> </td> <td> <p> Series E </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Kinsa </p> </td> <td> <p> NY </p> </td> <td> <p> US </p> </td> <td> <p> Digital health </p> </td> <td> <p> Kinsa is the maker of first-ever FDA-cleared smartphone-connected thermometer </p> </td> <td> <p> Kleiner Perkins Caufield &amp; Byers (KPCB), FirstMark Capital, Andy Palmer, and others </p> </td> <td> <p> $9.6m </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> Lightpoint Medical </p> </td> <td> <p> Rickmansworth </p> </td> <td> <p> UK </p> </td> <td> <p> Surgery </p> </td> <td> <p> Lightpoint's two lead products EnLight and LightPath help surgeons detect cancer in real-time during surgery and reduce the need for repeat operations. </p> </td> <td> <p> Oxford Technology, Cambridge Capital Group, London Business Angels, Envestors, Ruffena Capital, and crowdfunding platform SyndicateRoom. </p> </td> <td> <p> &pound;2m ($3.1m) </p> </td> <td> <p> Series A </p> </td> <td> <p> Undisclosed </p> </td> </tr> <tr> <td> <p> BioM </p> </td> <td> <p> MA </p> </td> <td> <p> US </p> </td> <td> <p> Personal bionics </p> </td> <td> <p> The BiOM T2 System provides power assist to enhance the mobility of people with lower limb amputations. </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> $6m (includes some debt financing) </p> </td> <td> <p> Undisclosed </p> </td> <td> <p> Undisclosed </p> </td> </tr> </table> <p> <a href="http://www.clinica.co.uk/multimedia/archive/00245/Clinica_s_Private_F_245359a.zip">Download the Excel table here </a> </p> 
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 15

VC Funding 2014
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20160622T191355
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT062759
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 15

VC Funding 2014
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

349293
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T192230Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

fdf7266b-bc4e-462e-8c0e-a67081dd51ac
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T231355Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 14

sitecore\admin
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
